1. Canada Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
HLS Therapeutics Inc.

HLS Therapeutics Inc.

HLTRF
HLS Therapeutics Inc.US flagOther OTC
2.64
USD
- -
- -
82.57MMarket Cap
HLS Therapeutics Inc.
HLTRF
(Other OTC)

Recent

price

2.64

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
3.82
3.94
5.77
4.01
3.81
- -
2.18
2.97
2.28
1.84
1.77
1.86
1.9
1.95
1.78
1.75
1.73
Revenue per Share
0.21
0.6
0.83
0.49
0.66
-0.1
-0.6
-0.24
-0.92
-0.67
-0.48
-0.41
-0.73
-0.85
-0.62
-0.39
-0.26
Basic EPS, GAAP
0.98
0.76
0.95
0.88
0.94
-0.17
0.87
1.05
1.19
0.38
-1.11
0.37
0.21
0.48
0.25
0.49
0.53
Free Cash Flow per Basic Share
0.17
0.54
0.44
0.32
0.16
- -
- -
- -
0.04
0.15
0.15
0.16
0.15
0.07
- -
- -
- -
Dividend per Share
1.57
1.6
2.04
2.09
2.41
1.92
1.92
6.58
5.81
5.74
5.32
4.95
3.87
3.05
2.24
1.97
1.77
Book Value per Share
1.57
1.6
2.04
2.09
2.41
1.92
1.92
-4.82
-4.13
-2.38
-2.64
-2.11
-2.15
-2.02
-1.6
-1.41
-1.28
Tangible Book Value per Share
23
20
20
20
19
18
25
25
27
29
32
32
32
32
32
32
33
Basic Weighted Avg Shares
88
79
117
79
74
- -
54
75
61
54
56
60
61
63
57
56
56
Sales/Revenue/Turnover
8.55
21.15
18.86
15.7
21.88
- -
21.32
31.01
12.44
-8.55
-21.54
-10.47
-21.96
-16.41
-13.57
-7.4
-8.02
Operating Margin (%)
7
6
7
6
4
- -
27
32
32
33
33
30
34
32
23
22
22
Depreciation Expense
5
12
17
10
13
-2
-15
-6
-25
-20
-15
-13
-24
-28
-20
-12
-9
Net Income, GAAP
33.19
27.01
25.28
24.1
25.16
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
5.39
15.22
14.47
12.25
17.21
- -
-27.56
-8.12
-40.39
-36.1
-27.32
-21.86
-38.39
-43.65
-34.71
-22.4
-15.24
Profit Margin (%)
14
19
32
36
46
26
25
30
-7
16
10
16
13
17
13
3
1
Working Capital
- -
- -
- -
- -
- -
- -
- -
137
92
87
97
85
84
82
61
45
37
LT Debt
32
33
41
41
47
26
25
180
158
178
169
161
125
98
71
62
55
Total Equity
12.78
34.68
41.98
22.92
27.29
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
13
36.64
45.68
23.9
29.14
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
14
37.13
45.86
23.88
29.14
-4.76
-58.41
-5.94
-14.64
-11.61
-8.82
-7.95
-16.5
-24.69
-23.26
-18.69
-14.07
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
5
5
5
LT Borrowings
44
39
37
LT Finance Leases
1
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
31
31
31
Market Capitalization
107
94
94

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
29
29
31
Cash, Cash Equivalents & STI
12
12
14
Accounts Receivable, Net
7
7
8
Inventories
8
7
6
Total Current Liabilities
26
29
29
Payables & Accruals
11
10
9
ST Debt
5
5
5
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
52.39%
-17.93%
-13.56%
Free Cash Flow
-127.19%
-0.56%
93.13%
Net Income, GAAP
98.15%
3.35%
-36.76%
Sales/Revenue/Turnover
- -
-0.04%
-1.98%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
12
15
14
16
57
2025
13
14
14
15
56
2026
13
15
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.19
-0.18
-0.15
- -
-0.62
2025
-0.14
-0.09
-0.12
-0.04
-0.39
2026
-0.07
-0.03
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
The Green Organic Dutchman Holdings Ltd. (GRODF)
Towa Pharmaceutical Co., Ltd. (4553.T)
Sunniva Inc. (SNN.CN)
Mega Lifesciences Public Company Limited (MEGA.BK)
Biofil Chemicals and Pharmaceuticals Limited (BIOFILCHEM.NS)
LanZhou Foci Pharmaceutical Co.,Ltd. (002644.SZ)
Business
HLS Therapeutics Inc is a specialty pharmaceutical company focused on the acquisition and commercialization of branded pharmaceutical products primarily in the North American markets, including Canada and the United States. Its core product portfolio consists of Clozaril, an atypical antipsychotic indicated for treatment-resistant schizophrenia; Vascepa, icosapent ethyl capsules prescribed for cardiovascular risk reduction; and CSAN Pronto, a capillary point-of-care medical device designed to simplify mandatory safety blood monitoring for patients on Clozaril. The company operates in central nervous system (psychiatric disorders) and cardiovascular therapeutic areas, delivering products that meet stringent FDA and Health Canada regulatory requirements. Founded in 2002 and headquartered in Toronto, Canada, HLS maintains operations in the Toronto, Montreal, and Philadelphia metropolitan areas. In recent years, HLS Therapeutics has undergone significant strategic changes including the streamlining of its operating model and strengthening of its balance sheet with substantial debt repayments to improve financial flexibility and future profitability prospects. In 2024, the company transitioned its go-to-market model for Vascepa from Pfizer back to internal management to enhance return on investment after evaluating sales performance. HLS has emphasized growth in its promoted product portfolio while reducing operating expenses to position itself for top-line growth and increased profitability moving into 2025. The company also continues to enhance its CSAN Pronto device to improve safety monitoring for Clozaril patients and pursues portfolio expansion initiatives to fuel long-term growth. HLS Therapeutics serves healthcare providers and patients by ensuring reliable market access to trusted branded medicines in its specialty CNS and cardiovascular niches. It generates revenue primarily through product sales augmented by royalties. The company’s strategic focus is on addressing unmet medical needs with clinically differentiated therapies, leveraging partnerships and in-licensing to expand its commercial offerings. With a relatively lean workforce of approximately 90 employees, HLS Therapeutics aims to consolidate its leadership in specialty pharmaceutical acquisitions and commercialization across North America while actively managing operational efficiencies and product demand growth strategies.

Company News

Company News APIChatGPT

  • marketbeat.com

    HLS Therapeutics Q2 Earnings Call Highlights

  • marketbeat.com

    HLS Therapeutics Q1 Earnings Call Highlights

  • seekingalpha.com

    HLS Therapeutics Inc. (HLS:CA) Q4 2025 Earnings Call Transcript